#64 ❤️🩹 Healthspan vs Lifespan The Future of Longevity with Cytonics
Most people talk about lifespan. We obsess over how long…
Engineering the Future of Joint Health with Molecular Precision
Cytonics is a clinical-stage biotechnology research and development company developing groundbreaking treatments for osteoarthritis (OA), the world’s most common
joint disease.
Leveraging the power of Alpha-2-Macroglobulin (A2M), a naturally occurring protein found in the blood, Cytonics has engineered a novel biologic that targets the root molecular drivers of
cartilage degradation. If approved by the FDA, it could become the first treatment to effectively halt, or even reverse osteoarthritis progression, offering relief where current medications fall short.
In Pursuit of the First Disease-Modifying Therapy for Osteoarthritis
Succeeding Where Big Pharma Has Failed
We understand why Big Pharma has been unable to develop a disease-modifying OA therapy, and out A2M-based therapeutic platform addresses their deficiencies.
Nature’s Blueprint, Perfected
Our first-generation OA therapy leverages the therapeutic power of the natural A2M protein. Now, we are “perfecting” Nature’s Design with CYT-108, our novel “super A2M” biopharmaceutical in FDA clinical trials.
For the People, By the People
Biopharma is almost exclusively capitalized and owned by Venture Capitalists, Wall Street funds, and Big Pharma. Cytonics is flipping this script and placing the power in the hands of those that need us to succeed the most: The People.
Our Mission
Pioneering Innovation In Drug Discovery
Big Pharma has failed to develop a true disease-modifying therapy for osteoarthritis (OA), leaving patients with ineffective palliative measures like corticosteroids and painkillers. Cytonics finds this current state-of-the-medicine to be unacceptable and have identified the root cause of Big Pharma’s repeated failures. And we know what to do about it.
Cytonics’ A2M-based platform directly addresses Big Pharma’s myopic approach to drug development, wherein they attempt to identify a single drug (e.g., a small molecule or more complex biologic) that affects a single target (e.g., a receptor on a cell) to have a singular effect. The problem is that OA is a multifactorial disease. A true disease-modifying OA therapy must address these multiple underlying causes to actually target the root molecular causes of the disease and offer patients long-term, durable relief. And that’s precisely what we are building.
Novel Therapeutic Modality
CYT-108 blocks the enzymes that destroy cartilage, offering a disease-modifying therapy that targets the root cause of OA not just the symptoms.
Disrupting Big Pharma
Our A2M-based therapies address the root cause of Big Pharma's failed attempts by targeting all of the enzymes responsible for osteoarthritis.
Iterating on Nature’s Design
Our therapeutic platform leverages the anti-protease activity of the natural A2M protein to potently treat cartilage damage and joint inflammation.
Rener & Eve Gracie
Big News: The Gracies Join Cytonics
We’re thrilled to welcome professional athletes and renowned health advocates, Rener and Eve Gracie, to the Cytonics mission. Known for their leadership in martial arts, fitness, and community empowerment, the Gracies bring a passionate voice to our fight against osteoarthritis. Together, we’re championing a future where movement is pain-free and healing starts at the molecular level.
Contact Us
Join The Movement
#mc_embed_signup{background:#fff; false;clear:left; font:14px Helvetica,Arial,sans-serif; width: 600px;}
/* Add your own Mailchimp form style overrides in your site stylesheet or in this style block.
We recommend moving this block and the preceding CSS link to the HEAD of your HTML file. */
(function($) {window.fnames = new Array(); window.ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';fnames[1]='FNAME';ftypes[1]='text';fnames[3]='MMERGE3';ftypes[3]='phone';fnames[2]='MMERGE2';ftypes[2]='text';}(jQuery));var $mcj = jQuery.noConflict(true);
* indicates required
() -
From our blog
News and insights
#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach
You may have seen the recent headlines regarding a breakthrough…
#62 🙏 Another Year Full of Gratitude
As the year concludes, Joey Bose reflects on gratitude towards…
#mc_embed_signup{background:#fff; false;clear:left; font:14px Helvetica,Arial,sans-serif; width: 600px;}
/* Add your own Mailchimp form style overrides in your site stylesheet or in this style block.
We recommend moving this block and the preceding CSS link to the HEAD of your HTML file. */
(function($) {window.fnames = new Array(); window.ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';fnames[1]='FNAME';ftypes[1]='text';fnames[3]='MMERGE3';ftypes[3]='phone';fnames[2]='MMERGE2';ftypes[2]='text';}(jQuery));var $mcj = jQuery.noConflict(true);
Subscribe
* indicates required
() -
